(Q46010882)

English

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

scientific article published on 26 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

pharmacokinetics

1 reference

based on heuristic

inferred from title

Cristina Papayannidis

object named as

Cristina Papayannidis

3

0 references

Hagop Kantarjian

12

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

Giovanni Martinelli

1

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

Michele Baccarani

11

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

Jorge Eduardo Cortes

14

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

Jerald P Radich

10

object named as

Jerald Radich

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Vivian G Oehler

2

object named as

Vivian G Oehler

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Catriona Jamieson

15

object named as

Catriona Jamieson

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

author name string

Rachel Courtney

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

M Naveed Shaik

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Xiaoxi Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Ashleigh O'Connell

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Karen R McLachlan

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Xianxian Zheng

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Wendy J Levin

13

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

publication date

26 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

The Lancet. Haematology.

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

e339-46

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Hedgehog signaling in animal development: paradigms and principles

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular pathways: the hedgehog signaling pathway in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting hedgehog in hematologic malignancy.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Essential role of stromally induced hedgehog signaling in B-cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hedgehog signaling maintains chemoresistance in myeloid leukemic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

GLI2 inhibition abrogates human leukemia stem cell dormancy

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hedgehog pathway as a drug target: Smoothened inhibitors in development

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hedgehog signaling pathway and cancer therapeutics: progress to date

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900096-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3026(15)00096-4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/26688487

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46010882&oldid=2143605521"